



Università degli Studi di Roma "Tor Vergata"

CURRICULUM DIDATTICO-SCIENTIFICO DEL PROF. ANDREA MODESTI

DATI PERSONALI

Nome e Cognome: Andrea Modesti

Luogo e data di nascita: Imperia (IM) 15 dicembre 1950

ATTUALE POSIZIONE:

Professore Ordinario di Patologia Generale

Dipartimento: Scienze Cliniche e Medicina Traslazionale

Indirizzo: Via Montpellier 1

Numero studio: +390672596518

E-mail: modesti@uniroma2.it

Orario ricevimento: tutti i giorni previo appuntamento

Settore scientifico-disciplinare: MED/04

ATTIVITA' DIDATTICO - SCIENTIFICA

Titoli accademici e di studio:

Diploma di Maturità Scientifica

Laurea in Medicina e Chirurgia con 110/110 e lode, Università Degli Studi di Roma "La Sapienza"

Specializzazione in Patologia generale con 70/70 e lode, Università Degli Studi di Roma "La Sapienza"

Curriculum Universitario

1980/87 tecnico Laureato presso la cattedra di Patologia generale, Università di Roma "La Sapienza"

1987/90 Professore Associato di Patologia generale, Università di Roma "La Sapienza"

1990/96 Professore Ordinario di Patologia generale, Università di Chieti G.D'Annunzio

dal 1996 Professore Ordinario di Patologia Generale, Università di Roma Tor Vergata

Incarichi

dal 2002 componente della Commissione didattica del Corso di Laurea Specialistica in Medicina e Chirurgia, Università di Roma Tor Vergata; **dal 2003 al 2009** Presidente del Corso di Laurea Specialistica in Medicina e Chirurgia, Università di Roma Tor Vergata; **dal 2006** membro del consiglio direttivo della SIP Società Italiana Patologia; **dal 2006 al 2013** Direttore della Scuola di specializzazione in Oncologia Medica; **dal 2013** Direttore del Dipartimento di Scienze Cliniche e Medicina Traslazionale

EDITORIAL BOARD

European Journal of Inflammation

SOCIETA'

Membro della SIP Società Italiana Di Patologia,

Socio Ordinario dell'Accademia Medica Di Roma

Socio della Società Italiana di Ricerche Cardiovascolari

LABORATORI FREQUENTATI ALL'ESTERO

Sezione di Ultrastruttura del Laboratorio di Patologia del National Cancer Institute, National Institutes of Health USA

INSEGNAMENTI DI PATOLOGIA GENERALE E/O FISIOPATOLOGIA GENERALE

Facoltà di Medicina e chirurgia; Laurea Specialistica in Medicina e Chirurgia; Laurea Specialistica in Biotecnologie mediche; Laurea triennale Podologia; Laurea triennale Tecniche diagnostiche Neuro-fisiopatologiche; Laurea triennale Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare.

Scuole di specializzazione: Oncologia, Patologia clinica, Chirurgia pediatrica, Anatomia patologica, Genetica medica

Principali Linee di Ricerca finanziate

Studio della produzione di matrice extracellulare da parte di tumori pediatrici- **SP Oncologia CNR**;
Modificazioni della matrice extracellulare in relazione all'espressione di proto-oncogeni- **SP ACRO, CNR**
Ruolo delle cellule normali peritumorali nella progressione neoplastica-**A.I.R.C.**

Linee di Ricerca finanziate (1998-2006)

1998 - Responsabile UO: "L'interferon-alfa nelle strategie immunologiche di prevenzione e cura di adenocarcinomi spontanei in topi transgenici ad alto rischio di neoplasia". Progetto nazionale dal titolo "Citochine come adiuvanti nella preparazione di vaccini di nuova generazione". Programma per la ricerca finalizzata. Ministero della Sanità - **2000-2002** - Responsabile UO: Recettori della famiglia ErbB e matrice extracellulare nelle neuropatie demielinizzanti ereditarie, Murst; **2002-2004** - Responsabile UO "Mediatori molecolari dell'interazione assone-cellula di Schwann nelle neuropatie demielinizzanti ereditarie". Progetto nazionale "Neuropatie ereditarie associate a mutazione delle proteine mieliniche: dissezione dei geni, patologia molecolare e meccanismi patogenetici della degenerazione assonale secondaria". Programmi di ricerca scientifica di rilevante interesse nazionale. Murst; **2005** - Responsabile UO "Diversified active specific immunotherapy targeting ErbB2/Neu in combination with external beam radiation to cure established mammary carcinomas". "Molecular targets and signaling in breast cancer progression. Progetto AIRC; **2005-2007** - Responsabile dell'unità operativa "Identificazione di antigeni tumorali per la diagnosi e la terapia del mesotelioma maligno". Progetto nazionale "Strategie innovative per la diagnosi e la terapia del mesotelioma maligno della pleura". Prin.

Research activity: 15 most significant publications

- 1) Masuelli L, ..., and **Modesti A**. In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma. **Front Pharmacol**. 2017,8:373.
- 2) Masuelli L, ..., and **Modesti A** Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. **Oncotarget**. 2017,8:34405.
- 3) Benvenuto M, ..., and **Modesti A** *In vitro* and *in vivo* inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. **Oncotarget** 2016,7:9250.
- 4) Fantini M, ..., and **Modesti A** In Vitro and In Vivo Antitumoral Effects of Combination of Polyphenols or Polyphenol/s and Anticancer Drugs: Perspectives on Cancer Treatment. **Int J Mol Sci**. 2015,16:9236.
- 5) Benvenuto M, ..., and **Modesti A** Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. **J Transl Med** 2015,13:101.
- 6) Masuelli L, ..., and **Modesti A** Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. **Oncotarget**. 2014,5(21):10745.
- 7) Masuelli L, ..., and **Modesti A** Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. **J Transl Med**. 2014,12:122.
- 8) Izzi V, ..., and **Modesti A** Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. **Cancer Lett**. 2012,322(1):18.
- 9) Masuelli L, ..., and **Modesti A** Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/ α - β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. **J Cell Physiol**. 2012,227(9):3344.
- 10) Masuelli L, ..., and **Modesti A** Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. **Cancer Immunol Immunother**. 2010,59(8):1247.
- 11) Albonici L, ... and **Modesti A**. Placenta growth factor is a survival factor for human malignant mesothelioma cells. **Int J Immunopathol Pharmacol**. 2009 Apr-Jun;22(2):389-401.
- 12) Santarelli R, ... and **Modesti A**. Identification and characterization of the product encoded by ORF69 of Kaposi's sarcoma-associated herpesvirus. **J Virol**. 2008 May;82(9):4562-72.
- 13) Masuelli L, ... and **Modesti A**. Intercalated disk remodeling in delta-sarcoglycan-deficient hamsters fed with an alpha-linolenic acid-enriched diet. **Int J Mol Med**. 2008 Jan;21(1):41-8.
- 14) Fiaccavento R, ... and **Modesti A**. Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters. **Am J Pathol**. 2006 Dec;169(6):1913-24.
- 15) Bei R, ..., and **Modesti A**. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. **J Pathol**. 2004,204(3):317.



ACADEMIC AND SCIENTIFIC CURRICULUM OF PROF. ANDREA MODESTI

PERSONAL DATA

Name and Surname: Andrea Modesti

Place and date of birth: Imperia (IM) december 15th, 1950

CURRENT POSITION: Full Professor of General Pathology

Department: Clinical Sciences and Translational Medicine

Address: Via Montpellier 1

Phone number: +390672596518

E-mail: modesti@uniroma2.it

Consulting hours: all days by schedule

Italian Ministry of Education Academic-Scientific sector: MED/04

SCIENTIFIC AND DIDACTIC ACTIVITY

Degrees

MD Degree : 110/110 cum laude, University of Rome "La Sapienza"

Residency in General Pathology: 70/70 cum laude, University of Rome "La Sapienza"

Academic Qualifications

1980/87 Technical Graduate, Department of General Pathology, University of Rome "La Sapienza"

1987/90 Associate Professor of General Pathology, University of Rome "La Sapienza"

1990/96 Full Professor of General Pathology, University of Chieti "G. D'Annunzio"

1996/present Full Professor of General Pathology, University of Rome "Tor Vergata"

2002/present Component of the Teaching Commission for Medical Doctor Degree, University of Rome "Tor Vergata"

2003/2009 President of Medical Doctor Degree, University of Rome "Tor Vergata"

2006/present Member of the Directive Council of SIP, Italian Society of Pathology

2006/2013 Chief, postgraduate School of Oncology, University of Rome "Tor Vergata"

2013/present Chief of the Department of Clinical Sciences and Traslational Medicine, University of Rome "Tor Vergata"

International laboratories attended

Ultrastructure Section at the Department of Pathology of National Cancer Institute, NIH, USA

Teaching activities

Faculty of Medicine and Surgery

Medical Doctor Degree, Medical Biotechnology Degree

Podology Degree, Neuro-physio-pathological diagnostic techniques Degree

Techniques of Cardiovascular physiopathology and perfusion Degree

Residency in Oncology, in Clinical Pathology, in Pediatric Surgery, in Pathological Anatomy

Research Projects

-1983-88: Supervisor of the operative unit on "Production of extracellular matrix in pediatric tumors". Oncology project, CNR.

-1991-96: Supervisor of the operative unit on "Modification of the extracellular matrix in relation with tumor progression". Project ACRO, CNR.

-1998-00: Supervisor of the operative unit on "Study of extracellular matrix remodelling in demyelinating inherited neuropathies" in the national project "Inherited neuropathies: physiopathology and molecular basis" MURST ex 40%.

-1999-01: Supervisor of the operative unit on "Interferon-alpha in immunologic approaches for prevention and therapy of spontaneous adenocarcinomas in transgenic mice with high cancer risk" in the national project "Cytokines as adjuvants in the preparation of new generation vaccines". Ministero della Sanità.

- 2000-02**: Supervisor of the operative unit on “ErbB family receptors and extracellular matrix in demyelinating inherited neuropathies” in the national project “Inherited neuropathies: identification of new genes, molecular and cellular pathology”. MURST ex 40%.
- 2002-04**: Supervisor of the operative unit on “Molecular mediators of axon-Schwann cells interaction in inherited demyelinating neuropathies” in the national project “Inherited neuropathies associated with myelin proteins mutations: dissection of genes, molecular pathology and pathogenic mechanisms of secondary axonal degeneration”. MIUR.
- 2003-05**: Supervisor of operative unit in the project “Autoimmune thyroiditis and skin: molecular mechanisms of cutaneous alterations and uninvase diagnostic techniques”. Ministero della Salute-Programmi speciali.
- 2005**: Supervisor of the operative unit on "Diversified active specific immunotherapy targeting ErbB2/Neu in combination with external beam radiation to cure established mammary carcinomas" in the AIRC Project "Molecular targets and signaling in breast cancer progression".
- 2005-2007** Supervisor of the operative unit on “Identification of neoplastic antigens for the diagnosis and therapy of malignant mesothelioma”. National project “Innovative strategies for the diagnosis and therapy of pleuric malignant mesothelioma”, Prin.

Research activity: 15 most significant publications

- 1) Masuelli L,...., and **Modesti A**. In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma. **Front Pharmacol**. 2017,8:373.
- 2) Masuelli L,...., and **Modesti A** Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. **Oncotarget**. 2017,8:34405.
- 3) Benvenuto M,...., and **Modesti A** *In vitro* and *in vivo* inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. **Oncotarget** 2016,7:9250.
- 4) Fantini M,...., and **Modesti A** In Vitro and In Vivo Antitumoral Effects of Combination of Polyphenols or Polyphenol/s and Anticancer Drugs: Perspectives on Cancer Treatment. **Int J Mol Sci**. 2015,16:9236.
- 5) Benvenuto M,...., and **Modesti A** Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. **J Transl Med** 2015,13:101.
- 6) Masuelli L,...., and **Modesti A** Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. **Oncotarget**. 2014,5(21):10745.
- 7) Masuelli L,...., and **Modesti A** Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. **J Transl Med**. 2014,12:122.
- 8) Izzi V,...., and **Modesti A** Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. **Cancer Lett**. 2012,322(1):18.
- 9) Masuelli L,...., and **Modesti A** Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/ α - β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. **J Cell Physiol**. 2012,227(9):3344.
- 10) Masuelli L,..., and **Modesti A** Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. **Cancer Immunol Immunother**. 2010,59(8):1247.
- 11) Albonici L, ... and **Modesti A**. Placenta growth factor is a survival factor for human malignant mesothelioma cells. **Int J Immunopathol Pharmacol**. 2009 Apr-Jun;22(2):389-401.
- 12) Santarelli R, ... and **Modesti A**. Identification and characterization of the product encoded by ORF69 of Kaposi's sarcoma-associated herpesvirus. **J Virol**. 2008 May;82(9):4562-72.
- 13) Masuelli L, ... and **Modesti A**. Intercalated disk remodeling in delta-sarcoglycan-deficient hamsters fed with an alpha-linolenic acid-enriched diet. **Int J Mol Med**. 2008 Jan;21(1):41-8.
- 14) Fiaccavento R, ... and **Modesti A**. Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters. **Am J Pathol**. 2006 Dec;169(6):1913-24.
- 15) Bei R,...., and **Modesti A**. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. **J Pathol**. 2004,204(3):317.